IMNM
Immunome, Inc.
$28.75
-0.64
(-2.16%)
Mkt Cap
2.75B
Volume
0
52W Range
8.665-30.06
Sector
Healthcare
Beta
2.12
EPS (TTM)
-2.54 USD
P/E Ratio
-8.84
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.94M | 9.04M | 14.02M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.39M) | (292.96M) | (106.81M) | (36.90M) | (24.71M) | (17.84M) | (10.55M) | (7.84M) |
| EPS | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -1.69 | -1.84 | -7.18 |
| Free Cash Flow | (200.60M) | (164.30M) | (8.40M) | (28.94M) | (18.30M) | (12.72M) | (9.83M) | (7.63M) |
| FCF / Share | -2.30 | -2.80 | -0.42 | -2.39 | -1.59 | -1.26 | -1.71 | -6.99 |
| Operating CF | (190.92M) | (110.79M) | (7.57M) | (28.69M) | (18.23M) | (12.13M) | (9.60M) | (7.41M) |
| Total Assets | 683.19M | 240.24M | 148.54M | 24.05M | 57.92M | 44.52M | 5.06M | 4.45M |
| Total Debt | 3.85M | 4.83M | 1.65M | 291,000 | 317,000 | 613,000 | 564,000 | 1.18M |
| Cash & Equiv | 653.48M | 143.35M | 98.68M | 20.32M | 49.23M | 39.77M | 2.54M | 1.60M |
| Book Value | 634.34M | 181.16M | 119.88M | 16.65M | 48.19M | 41.34M | (35.63M) | (25.20M) |
| Return on Equity | -0.33 | -1.62 | -0.89 | -2.22 | -0.51 | -0.43 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 4.01M | 2.93M | 2.74M | 2.91M | 2.36M | 1.03M | 3.83M | 3.56M |
| Net Income | (73.13M) | (53.84M) | (69.90M) | (57.46M) | (43.40M) | (41.64M) | (80.25M) | (47.10M) | (36.12M) | (129.49M) | (92.63M) | (4.34M) |
| EPS | -0.65 | -0.48 | -0.76 | -0.65 | -0.50 | -0.52 | -1.28 | -0.78 | -0.60 | -12.56 | -4.22 | -0.36 |
| Free Cash Flow | (63.87M) | (61.64M) | (51.95M) | (41.63M) | (50.31M) | (56.72M) | (43.44M) | (35.71M) | (25.74M) | (13.33M) | (17.81M) | (8.65M) |
| FCF / Share | -0.56 | -0.54 | -0.59 | -0.47 | -0.58 | -0.71 | -0.69 | -0.59 | -0.43 | -1.29 | -0.81 | -0.71 |
| Operating CF | (61.69M) | (58.64M) | (47.95M) | (40.51M) | (49.40M) | (53.05M) | (42.06M) | (34.17M) | (23.40M) | (11.17M) | (17.46M) | (8.61M) |
| Total Assets | 565.38M | 619.79M | 683.19M | 299.38M | 296.29M | 342.69M | 240.24M | 256.90M | 296.21M | 319.75M | 148.54M | 93.16M |
| Total Debt | 4.59M | 3.69M | 3.85M | 4.01M | 4.14M | 4.77M | 4.83M | 2.72M | 2.77M | 1.62M | 1.65M | 371,000 |
| Cash & Equiv | 217.71M | 582.69M | 653.48M | 272.64M | 143.88M | 257.61M | 143.35M | 155.57M | 165.33M | 269.72M | 98.68M | 90.64M |
| Book Value | 525.08M | 588.69M | 634.34M | 263.92M | 269.27M | 307.13M | 181.16M | 214.91M | 253.84M | 285.57M | 119.88M | 6.08M |
| Return on Equity | -0.14 | -0.09 | -0.11 | -0.22 | -0.16 | -0.14 | -0.44 | -0.22 | -0.14 | -0.45 | -0.77 | -0.72 |
IMNM News
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
What This Immunome Sale Means a Day Before a Big FDA Milestone
Immunome Stock Up 32% in a Month: Here's What You Should Know
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors